• Explore /
  • Poster
  • / Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.

Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.

Abstract Poster

Authors

null

Chang Gon Kim

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Chang Gon Kim , Min Hee Hong , Da Hee Kim , Sun Min Lim , Brian Lee , Yoon Ji Bang , Se-Heon Kim , Young Min Park , Kyoung-Ho Pyo , Jae Hwan Kim , Heejung Park , Goeun Park , Inkyung Jung , Seunghee Kim-Schulze , Miriam Merad , Byoung Chul Cho , Hyun Je Kim , Yoon Woo Koh , Hye Ryun Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT03737968

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6072)

DOI

10.1200/JCO.2022.40.16_suppl.6072

Abstract #

6072

Poster Bd #

64

Abstract Disclosures

Similar Posters

First Author: Markus Hecht

First Author: Maria M Rubinstein

First Author: Tanguy Y. Seiwert

First Author: Lillian L. Siu